CoChat
Sign Up
Cited by 100Endometriosis Research and TreatmentGynecological conditions and treatmentsEndometrial and Cervical Cancer Treatments

Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis

Open access
Razzi, Sandro, Luisi, Stefano, Calonaci, Francesco, Altomare, Aldo, Bocchi, Caterina, Petraglia, Felice·2007·Fertility and Sterility
DOI 10.1016/j.fertnstert.2006.12.077
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective To describe a safe long-term medical treatment for deeply infiltrating endometriosis, a critical condition characterized by multiple painful symptoms and a high recurrence rate after surgical treatment.Design Prospective study.Setting University of Siena.Patient(s) Twenty-one women with deeply infiltrating endometriosis.Intervention(s) In a nonrandomized prospective study a low dose of vaginal danazol (200 mg/d) was self-administered for 12 months. After a previous laparoscopic surgery, these patients had reported recurrent severe dyspareunia, dysmenorrhea, and pelvic pain (in five cases also painful defecation).Main outcome measure(s) Before and every 3 months during the treatment a visual analogue pain scale was used. Transvaginal and transrectal ultrasound examinations were performed before and after 6 and 12 months of treatment. Adverse effects were registered, and serum concentration of cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glycemia, protein S, protein C, antithrombin III, and homocysteine was evaluated before and after 12 months.Result(s) Dysmenorrhea, dyspareunia, and pelvic pain significantly decreased within 3 months and disappeared after 6 months of treatment, with a persistent effect during the 12 months of treatment. A relief of painful defecation was also shown. Ultrasound examination showed a reduction of the nodularity in the rectovaginal septum within 6 months. The medical treatment did not affect metabolic or thrombophilic parameters; few local vaginal adverse effects were reported.Conclusion(s) Vaginal danazol resulted in effective medical treatment for the various painful symptoms in women with recurrent deeply infiltrating endometriosis, and because of the lack of significant adverse effects it may be proposed as an alternative to repeated surgery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fertnstert.2006.12.077

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with DIE, vaginal danazol significantly reduces painful symptoms, with fewer recurrences and decreased volume of endometriosis lesions.

    “A significant reduction of painful symptoms in patients with DIE was observed, with less recurrences and a decreased volume of endometriosis lesions [223].”

    From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [223]

    The Results (p. 1) report significant reductions in painful symptoms, and the Discussion (p. 3) says vaginal danazol reduced lesion size. The paper describes women whose symptoms had recurred after surgery, but it does not report that vaginal danazol led to fewer recurrences. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Danazol-loaded intrauterine device and off-label vaginal danazol (200 mg/day) have good efficacy and better tolerability, particularly for women with deep infiltrating endometriosis (DIE) and rectovaginal endometriosis.

    “Good efficacy and better tolerability has been reported with danazol-loaded intrauterine device [221] and with off-label vaginal administration (200 mg/day) [222, 223], particularly for women with DIE and rectovaginal endometriosis [224].”

    From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [223]

  • A TSEC containing BZA and conjugated estrogens decreased endometriotic lesion size in a mouse model.

    “A tissue-selective estrogen complex (TSEC) containing BZA and conjugated estrogens (CE) also decreased endometriotic lesion size in a mouse model.”

    From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [223]

    Materials and Methods (p. 2) describes a study of vaginal danazol in women, and the Discussion (p. 3) reports reduced lesion size with that treatment. Searches for BZA, conjugated estrogens, and a mouse model found no passage addressing the claimed TSEC result; the danazol finding neither supports nor contradicts it. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

  • Adding estrogens to BZA did not induce endometrial growth or hyperplasia and did not reduce SERM efficacy.

    “The addition of estrogens to BZA did not induce endometrial growth or endometrial hyperplasia and did not reduce the efficacy of the SERM [223].”

    From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [223]

    The treatment description (p. 2) identifies vaginal danazol, not BZA, as the drug studied. The discussion (p. 5) says low-dose danazol did not modify endometrial thickness, but it does not address adding estrogens to BZA, endometrial hyperplasia, or SERM efficacy. Searches for BZA, bazedoxifene, and those outcomes found no passage supporting the attributed claim. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [10]10. with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005;84:1357-87.

Cited by

Sorted by citations

Related

Authors
Razzi, S., Luisi, S., Calonaci, F., Altomare, A., Bocchi, C., & Petraglia, F.
Affiliations
University of Siena (IT)
Corresponding author
Petraglia, Felice
ORCID
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2007-10
Volume
88
Issue
4
Pages
789-794
ISSN
0015-0282 (ISSN-L)
DOI
10.1016/j.fertnstert.2006.12.077
OpenAlex
W2159777458
Cited by
100
References
26
Citations by year
2026: 4 · 2025: 6 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 8 · 2019: 3 · 2018: 3 · 2017: 8 · 2016: 3 · 2015: 8 · 2014: 4 · 2013: 4 · 2012: 5
FWCI
5.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
deep infiltrating endometriosis, recurrent endometriosis, dysmenorrhea, dyspareunia, pelvic pain, painful defecation, thrombophilia
MeSH terms
Administration, Intravaginal, Adult, Danazol, Endometriosis, Female, Humans, Prospective Studies, Recurrence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review